Epstein-Barr virus nuclear antigen peptide-HLA class I complex (EBNA-HLA-I complex)

The Epstein-Barr virus nuclear antigen (EBNA) peptide-HLA class I complex is a molecular assembly consisting of short peptide fragments derived from EBV nuclear proteins (such as EBNA1, EBNA2, or the EBNA3 family) bound within the groove of Human Leukocyte Antigen (HLA) class I molecules on the cell surface (Hislop et al., 2007, Annu Rev Immunol). These complexes serve as critical epitopes for the immune system, specifically for CD8+ cytotoxic T lymphocytes, which recognize them via their T-cell receptors (TCRs). In EBV-infected or EBV-transformed cells, such as those found in post-transplant lymphoproliferative disorder (PTLD) or nasopharyngeal carcinoma, these complexes are constitutively presented, making them ideal targets for immunotherapy (Prock et al., 2023, Blood). Therapeutic strategies include the use of allogeneic EBV-specific T cells, such as tabelecleucel (Ebvallo), which is approved for EBV-positive PTLD (Dhillon, 2023, Drugs). Additionally, TCR-engineered T cells and TCR-like antibodies are being developed to target specific EBNA-derived epitopes with high affinity. Because these targets are highly specific to virally infected cells, they offer a pathway for precision oncology, although they are limited by the requirement for specific HLA matching in patients. Notable safety concerns include potential off-target cross-reactivity with self-peptides and the risk of cytokine release syndrome during T-cell activation.

Other names

EBNA-MHC class I complexEBV nuclear antigen peptide-MHC complexEBNA-HLA complexEBV-specific peptide-MHC complexEBNA1-HLA-A*02:01 complexEBNA3-HLA complexEpstein-Barr virus nuclear antigen-derived peptide-HLA class I complexes on EBV-infected or EBV-transformed cells

Recognition of the specific viral peptide-HLA complex by T-cell receptors (TCRs) or TCR-like antibodies, triggering cytotoxic T-lymphocyte (CTL) mediated cell death via perforin and granzyme release.